Health & Medications

Stopping a GLP-1? Make a Follow-Up Plan First

By Owen Marsh / October 20, 2026 / Updated November 8, 2026

Stethoscope and notebook arranged on a medical desk

Stopping a GLP-1 medicine does not end the need for care. On average, studies find that weight comes back after treatment stops, and some health measures drift back too. But the amount differs a great deal from one study and one person to the next. That is why a follow-up plan belongs in the conversation before any change, not after it. This guide, current as of November 2026, explains what the research shows, where it is thin, and what to ask your doctor or pharmacist.

Key takeaways

On average, weight returns after weight-management medicines are stopped. Speed and size vary.
A 2026 review in the BMJ, covering 37 studies, found average regain of about 0.4 kg (under 1 pound) a month.
A large real-world study found much smaller regain. That may be partly because many people restarted or switched medicines.
No method for stopping gently has been proven. Ideas such as tapering were not shown to prevent regain in the trials reviewed.
Ask for a written plan before any change: what to check, when, and whom to call.

What studies show after treatment stops

GLP-1 is short for glucagon-like peptide-1, a hormone released by the gut. GLP-1 medicines, such as semaglutide and tirzepatide, copy it. They are used for weight management and for type 2 diabetes.

Researchers have studied what happens next in two ways. In a randomized trial, people are assigned by chance to keep the medicine or switch to a placebo, which is a dummy pill or injection. That gives a clean comparison. A review that pools many studies, called a systematic review with meta-analysis, adds up their results.

Study	Who and how	What happened after stopping
SURMOUNT-4, JAMA, December 2023 (tirzepatide)	Randomized trial of 670 people, paid for by Eli Lilly. After 36 weeks on the medicine, they either continued or switched to placebo for 52 weeks.	Placebo group regained about 14 percent of body weight, roughly half of what they had lost, and stayed nearly 10 percent below their starting weight. Those who continued lost a further 5.5 percent.
STEP 1 extension (semaglutide), as summarized in a 2025 review	People who lost 17.3 percent on semaglutide over 68 weeks were followed for 52 weeks off treatment.	They regained 11.6 percentage points, against 1.9 for placebo. A percentage point is one percent of starting body weight. They were 5.6 percent below their starting weight at week 120.
BMJ, January 2026 (weight-management medicines in general)	Systematic review of 37 studies and 9,341 adults. Treatment averaged 39 weeks and follow-up 32 weeks.	Weight returned at about 0.4 kg a month, faster than after non-drug programs by about 0.3 kg a month.

The BMJ authors also projected that health markers, such as blood pressure, blood sugar and cholesterol, would return to their starting levels within about 1.4 years. That is an estimate beyond the follow-up actually observed, so treat it as a projection. In SURMOUNT-4, improvements in these markers also reversed in the placebo group.

Why your result may not match the averages

A study from Cleveland Clinic, announced on 12 March 2026 and published in the journal Diabetes, Obesity and Metabolism, shows how different real life can look. It was a retrospective study, meaning researchers looked back at existing records. It covered 7,938 adults in Ohio and Florida who started injectable semaglutide or tirzepatide and stopped within 3 to 12 months.

Those treated for obesity had lost 8.4 percent of body weight before stopping. One year later they had regained 0.5 percent on average. About 55 percent gained weight, and 45 percent kept losing or stayed the same. The group treated for type 2 diabetes lost another 1.3 percent on average, though about 44 percent gained.

These numbers look gentler than the trials, and there are possible reasons. These patients stopped fairly early and had lost less to begin with. Within a year, 27 percent had switched to another medicine and 20 percent had restarted their original one, so not everyone was truly off treatment. An earlier study by the same team found that cost or insurance limits were the main reason for stopping, with side effects next.

The lesson is not that one study is right and the others are wrong. Trials show what happens when people stop under controlled conditions. Real-world records show what people actually do. Neither can tell you your own outcome.

What may help, and what is not proven

In May 2025 four expert groups issued joint advice on nutrition during GLP-1 treatment: the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society. They name poor long-term use and weight regain as key challenges. They note that most people prescribed these medicines do not get enough nutrition counseling or behavioral support. They recommend enough protein and strength training to protect muscle.

That is guidance from expert groups, not proof that any routine prevents regain. The BMJ authors urge caution about short-term use of these medicines unless they come with a fuller weight-management approach.

On ways of stopping, the evidence is limited. A 2025 narrative review in the Journal of Clinical Medicine, which summarizes studies without pooling them, found only five placebo-controlled trials that measured weight after stopping. Only three were judged good enough in quality, and 11 of the 13 trials it examined were paid for by industry. Ideas such as tapering, which means lowering the dose gradually, and longer gaps between doses were suggested. None had been tested as a way to prevent regain in those trials. I found no support in these sources for a supplement or short routine that prevents regain.

Reasons people stop, and what to settle first

People stop for many reasons: cost, insurance rules, side effects, a change in health, or feeling that the goal is met. Whatever the reason, tell your prescriber. They may know options you do not, and they can only help if they know.

If the medicine also treats your diabetes, blood sugar needs a plan too. Ask how it will be checked afterward and whether your other medicines need review. Do not stop, restart or change doses because of this article or someone else’s story.

Building a follow-up plan with your care team

Here is one way to approach the conversation, step by step:

Say plainly why you are thinking about stopping.
Ask which health measures should be tracked, such as weight, blood pressure, blood sugar and cholesterol, and how often.
Ask what support is available, such as a dietitian or advice on strength exercises.
Ask what the plan is if weight or symptoms change, and what options exist then.
Ask about cost and coverage for any option you might need later.
Leave with the plan in writing, with dates and a phone number.

Checklist for the visit

A list of all my medicines and supplements, with doses.
The date I started my GLP-1 medicine and my highest dose.
My starting weight, current weight and recent test results, if I have them.
The reason I am thinking about stopping.
My insurance card and pharmacy details.
Someone to take notes with me.

Frequently asked questions

Will I regain all the weight if I stop?

Not necessarily. In SURMOUNT-4 the placebo group regained about half of what they lost, and in the STEP 1 extension about two thirds. In the Cleveland Clinic study the average regain was small. Averages hide individual differences.

Is there a safe way to taper?

No method has been proven. Tapering has been suggested but not tested for preventing regain in the trials reviewed. Ask your prescriber what they recommend for you.

If the weight comes back, did I fail?

No. Regain was seen across many studies, whatever the length of treatment. It is a health matter to plan for, not a personal failing.

What if I am stopping because of cost?

Say so. Cost and insurance were the most common reasons for stopping in the Cleveland Clinic team’s earlier study. Ask your doctor, pharmacist and plan about options, and do not change how you take the medicine to stretch a supply without asking first.

Before you decide

The research does not say that stopping is wrong or that staying on is right. It says that stopping calls for a plan. Bring the checklist, ask your questions and write down the answers. Any decision to start, stop or change a medicine belongs to you and your prescriber.